As therapies grow more personalized and molecularly complex, advancing them from lab to clinic depends not only on drug discovery, but on how those drugs are made. Frank Fazio, president of the Good Manufacturing Practices (GMP) Facility at St. Jude Children’s Research Hospital in Memphis, Tennessee, explains how close integration of research and production is helping reshape paediatric drug development — and accelerating the path from discovery to patient care.

How is biological insight reshaping drug safety?

Precision has improved dramatically. As we understand the underlying biology better, we’re selecting more relevant targets and pursuing them with greater confidence. We still encounter failures, but it feels less frequent because the biology is becoming clearer.